New! Sign up for our free email newsletter.
Science News
from research organizations

Diabetes medication class tied to lower risk of kidney stones

Date:
January 31, 2024
Source:
Mass General Brigham
Summary:
Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. Researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones.
Share:
FULL STORY

Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from Mass General Brigham, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in JAMA Internal Medicine.

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from Mass General Brigham, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in JAMA Internal Medicine.

Researchers from Brigham and Women's Hospital and Massachusetts General Hospital, founding members of the Mass General Brigham healthcare system, worked together to conduct the analysis. The study included data from three nationwide databases of patients with type 2 diabetes who were seen in routine clinical practice. The team analyzed information from 716,406 adults with type 2 diabetes who had started taking an SGLT2 inhibitor or two other classes of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors. Patients who began taking SGLT2 inhibitors had a 30 percent lower risk of developing kidney stones than those taking GLP1 agonists and about a 25 percent lower risk than those taking DPP4 inhibitors. The findings were consistent across sex, race/ethnicity, history of chronic kidney disease and obesity.

"Our findings could help inform clinical decision making for patients with diabetes who are at risk for developing kidney stones," said corresponding author Julie Paik, MD, ScD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medicine at Brigham and Women's Hospital.


Story Source:

Materials provided by Mass General Brigham. Note: Content may be edited for style and length.


Journal Reference:

  1. Julie M. Paik, Helen Tesfaye, Gary C. Curhan, Heidi Zakoul, Deborah J. Wexler, Elisabetta Patorno. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2024; DOI: 10.1001/jamainternmed.2023.7660

Cite This Page:

Mass General Brigham. "Diabetes medication class tied to lower risk of kidney stones." ScienceDaily. ScienceDaily, 31 January 2024. <www.sciencedaily.com/releases/2024/01/240131183518.htm>.
Mass General Brigham. (2024, January 31). Diabetes medication class tied to lower risk of kidney stones. ScienceDaily. Retrieved March 2, 2024 from www.sciencedaily.com/releases/2024/01/240131183518.htm
Mass General Brigham. "Diabetes medication class tied to lower risk of kidney stones." ScienceDaily. www.sciencedaily.com/releases/2024/01/240131183518.htm (accessed March 2, 2024).

Explore More
from ScienceDaily

RELATED STORIES